Research updates from Luvaminos
Subscribe for catalog updates, new research compounds, and quality documentation releases.
For researchers and labs. No spam — unsubscribe anytime.
Research updates from Luvaminos
Subscribe for catalog updates, new research compounds, and quality documentation releases.
For researchers and labs. No spam — unsubscribe anytime.
Peptide Analogs
A synthetic, C-terminally amidated hexapeptide incorporating two D-amino-acid substitutions, studied as a tool compound in class A GPCR structural pharmacology.
Reviewed by Dr. James Whitfield, PharmD · Published · Last reviewed · For research use only.
Type
Synthetic peptide (hexapeptide)
Molecular formula
C46H56N12O6
Molecular weight
873.0 g/mol
CAS number
87616-84-0
Amino acids
6
Sequence
His-D-Trp-Ala-Trp-D-Phe-Lys-NH2
Modification
D-Trp and D-Phe; C-terminal amide.
A synthetic hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, bearing a C-terminal amide and two D-amino-acid substitutions (D-Trp at position 2, D-Phe at position 5) that confer protease resistance to the L-amino-acid backbone. In structural-pharmacology studies it serves as a tool ligand for a class A GPCR, where the compact six-residue scaffold defines a distinct binding pose within the receptor's orthosteric pocket.
Lyophilized
20°C
typically stable 24-36 months desiccated.
Avoid freeze-thaw; aliquot; protect from light and moisture.
Reviews
Berlanga-Acosta J, et al. (2017). Clin Med Insights Cardiol
Berlanga-Acosta J, et al. (2016). Integr Mol Med
Clinical
Cabrales A, et al. (2013). Eur J Pharm Sci
Clinical
Bowers CY, et al. (1992). J Clin Endocrinol Metab
Peñalva A, et al. (1993). J Clin Endocrinol Metab
Popovic V, et al. (1995). J Clin Endocrinol Metab
Pandya N, et al. (1998). J Clin Endocrinol Metab
Micic D, et al. (1998). J Clin Endocrinol Metab
Veldhuis JD, Bowers CY (2009). Am J Physiol Endocrinol Metab
Hernández-Bernal F, et al. (2024). Front Neurol
Primary research
Bowers CY, et al. (1984). Endocrinology
McCormick GF, et al. (1985). Endocrinology
Howard AD, et al. (1996). Science
Demers A, et al. (2004). Biochem J
Lei T, et al. (1995). J Mol Endocrinol
Frago LM, et al. (2002). Endocrinology
Frago LM, et al. (2005). J Neuroendocrinol
Tung YC, et al. (2005). J Neuroendocrinol
Berlanga J, et al. (2007). Clin Sci (Lond)
Qiu WC, et al. (2008). World J Gastroenterol
García Del Barco D, et al. (2011). Neurotoxicol Res
García del Barco D, et al. (2011). Restor Neurol Neurosci
García Del Barco-Herrera D, et al. (2013). Restor Neurol Neurosci
Yahashi S, et al. (2012). Peptides
Subirós N, et al. (2016). Neurol Res
Mendoza Marí Y, et al. (2016). Plast Surg Int
Subirós N, et al. (2016). Neurol Res
Fernández-Mayola M, et al. (2018). Int Wound J
Berlanga-Acosta J, et al. (2024). Front Pharmacol
Wang L, et al. (2026). Pharmaceuticals (Basel)
Wang L, et al. (2026). Int Immunopharmacol
Research Use Only
These products are intended for research purposes only and are not for human consumption. Not FDA approved. Not intended to diagnose, treat, cure, or prevent any disease.
| Compound | Type | Molecular weight | CAS number |
|---|---|---|---|
| GHRP-6This page | Synthetic peptide (hexapeptide) | 873.0 g/mol | 87616-84-0 |
| LUV RT | Synthetic peptide (acylated, 39 residues) | ~4,731 Da | 2381089-83-2 |
| LUV SM | Synthetic peptide (acylated, 31 residues) | ~4,114 g/mol | 910463-68-2 |
| LUV TRZ2 | Synthetic linear peptide (acylated, 39 residues) | ~4,814 g/mol | 2023788-19-2 |
| AOD-9604 | Synthetic peptide (cyclic, 16 residues) | ~1,815 g/mol | 221231-10-3 |
Comparison of laboratory reference specifications only. For research use only; not a therapeutic comparison.
Quality & methods